Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Sadarangani gave a talk on the body's immune response to novel vaccines at the Winter Science Meeting 2015 at the Academy of Medical Sciences this month. His efforts to make the talk accessible and engage with a lay audience won him the Communications Prize.

The summary of Dr Sadarangani's project:

What is this project about? There are 500,000 cases of meningococcal disease (blood poisoning and meningitis) per year worldwide, and 1 in 10 people will die. A new meningococcal vaccine introduced in the UK in 2015 includes part of the bacterial membrane, known as an outer membrane vesicle or OMV. In this study we immunised 26 healthy adults with 3 doses of a new vaccine (MenPF) which also contains OMV. We tested their blood to look at how they responded to the vaccine and which genes were switched ‘on’ or ‘off’ after vaccination. 

Why is it important? We need to know more about vaccines which contain OMV to understand how to make better vaccines in the future - at the moment they often cause fever, and multiple doses are needed. No one has previously used genetic studies to address this.

What were the results? All participants responded well to the vaccine and had high antibody levels after 3 doses. Specific genes involved in injury and inflammation were switched on or off within 4-6 hours after the 1st dose. This tells us, for the first time, what is happening in the body very early after vaccination. A different set of genes were switched on or off 24 hours after the 3rd dose, and these are involved in a specific type of the body’s immune response. This information tells us exactly what is happening after vaccination and we may be able to use this to design better vaccines in the future, which cause fewer side effects and work better.

Similar stories

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

COVID-19 Vaccinology

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

COVID-19 Public Engagement Vaccinology

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

Human challenge trial launches to study immune response to COVID-19

COVID-19 Vaccinology

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Alternating vaccines trial expands to include two additional vaccines

COVID-19 Clinical Trials Vaccinology

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19 Vaccinology

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19 Vaccinology

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.